using grafts from donation after circulatory death (DCD) and donation after brain death (DBD).

Size: px
Start display at page:

Download "using grafts from donation after circulatory death (DCD) and donation after brain death (DBD)."

Transcription

1 Research Original Investigation PACIFIC COAST SURGICAL ASSOCIATION Liver Transplantation in Children Using Organ Donation After Circulatory Death A Case-Control Outcomes Analysis of a 20-Year Experience in a Single Center Johnny C. Hong, MD; Robert Venick, MD; Hasan Yersiz, MD; Prawat Kositamongkol, MD; Fady M. Kaldas, MD; Henrik Petrowsky, MD; Douglas G. Farmer, MD; Vatche Agopian, MD; Sue V. McDiarmid, MD; Jonathan R. Hiatt, MD; Ronald W. Busuttil, MD, PhD IMPORTANCE While orthotopic liver transplantation (OLT) is a durable life-saving treatment for patients with irreversible liver disease, the waiting list mortality rate for children younger than 6 years is 4 times higher than for children aged 11 to 17 years and adults owing to scarce availability of size-appropriate grafts for transplantation. OBJECTIVE To compare long-term outcomes for children (aged 18 years) undergoing OLT using grafts from donation after circulatory death (DCD) and donation after brain death (DBD). DESIGN, SETTING, AND PARTICIPANTS Retrospective study using case-control matched groups at a university transplant center. All patients aged 18 years and younger who underwent OLT using DCD organs between February 1, 1990, and November 30, 2010, at the University of California, Los Angeles, were matched in a 1 to 3 ratio with patients who received primary OLT from DBD donors within a 12-month period. Other matching criteria included recipient age, weight, cause of liver disease, and acuity of illness. Outcomes after OLT were compared for DCD (n = 7) and DBD (n = 21) donors. The median follow-up was 4.5 years. MAIN OUTCOMES AND MEASURES The primary outcome measure was graft failure free survival; the secondary end point was the development of ischemic cholangiopathy. RESULTS Comparing DCD and DBD groups, recipient median age (28.4 vs 20.1 months, respectively; P =.80), weight (12.0 vs 11.6 kg, respectively; P =.87), Model for End-Stage Liver Disease/Pediatric End-Stage Liver Disease score (19 vs 11, respectively; P =.48), and donor age (24.0 vs 13.1 months, respectively; P =.72) were similar. For the DCD donors, the median donor warm ischemia duration was 24 minutes. Liver test results were similar for both groups at 1 week and 3, 6, and 12 months following OLT. Ten-year patient and graft survival rates for both DCD and DBD were 100%. Neither ischemic cholangiopathy nor vascular complications occurred in the DCD group. Biliary anastomotic strictures occurred in 1 DCD patient and 3 DBD patients. CONCLUSIONS AND RELEVANCE Our study showed excellent long-term outcomes with liver transplantation in children using DCD organs. Use of liver grafts procured after circulatory death is an effective approach to expand the donor pool and remains an untapped resource for children with end-stage liver disease. JAMA Surg. 2014;149(1): doi: /jamasurg Published online November 20, Author Affiliations: Division of Transplant Surgery, Department of Surgery, Medical College of Wisconsin, Milwaukee (Hong); Department of Surgery, Dumont UCLA Liver Cancer and Transplant Centers, Pfleger Liver Institute, University of California, Los Angeles (Venick, Yersiz, Kositamongkol, Kaldas, Petrowsky, Farmer, Agopian, McDiarmid, Hiatt, Busuttil); Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles (Venick, McDiarmid). Corresponding Author: Johnny C. Hong, MD, Division of Transplant Surgery, Department of Surgery, Medical College of Wisconsin, 9200 W Wisconsin Ave, Ste E5700, Milwaukee, WI ( jhong@mcw.edu). 77

2 Research Original Investigation Liver Transplantation in Children Orthotopic liver transplantation (OLT) is a durable lifesaving treatment for patients with irreversible liver disease. Donor availability is the principal factor limiting expansion of OLT. This is a particular problem in small children, with scarce availability of size-appropriate grafts. In the current era, the waiting list mortality rate for children younger than 6 years is 4 times higher than for children aged 11 to 17 years. 1 United States law requires that criteria for brain death or circulatory death must be met prior to organ donation for transplantation. Brain death is defined as the irreversible cessation of all brain function including the brainstem, and circulatory death is defined as irreversible cessation of circulation and respiratory functions. Most organs today are retrieved from donation after brain death (DBD) donors. In contrast to liver grafts from DBD donors for which blood circulation and organ perfusion are maintained by the beating heart until initiation of organ preservation, organs from donation after circulatory death (DCD) donors are subjected to a period of absent blood flow before cold preservation can be administered. 2 Diminished quality and function of DCD liver grafts after transplantation have been attributed to an additional warm ischemic insult, which augments organ preservation injury. 3,4 Donation after circulatory death has been used to address the acute shortage of organs and to decrease waiting list mortality. Compared with patients who received DBD grafts, the long-term outcome data in adult recipients have shown inferior survival and higher rates of graft failure and ischemic cholangiopathy (diffuse intrahepatic ductal stricturing) for DCD grafts At present, the use of DCD grafts for children remains controversial and outcome data are limited. This study was undertaken to compare long-term outcomes after OLT in children using DCD and DBD grafts. Methods Data Collection and Study Design Using a prospectively maintained database, we performed a retrospective analysis of all patients aged 18 years and younger Figure. Phases of Ischemic Injuries for Organ Circulatory Death and After Brain Death Withdrawal of life support Donor warm ischemia time (organ and tissue hypoperfusion) Cardiopulmonary death Donation after circulatory death 5-min waiting time Cold preservation Graft cold ischemia time Donation after brain death Withdrawal of life support Graft warm ischemia time End of organ storage Graft reperfusion who underwent OLT using DCD organs between February 1, 1990, and November 30, 2010, at the University of California, Los Angeles (UCLA). This cohort of transplant recipients was matched in a 1 to 3 ratio with patients who received primary OLT from DBD donors within a 12-month period. The matching criteria included recipient age, weight, cause of liver disease, and acuity of illness. 11 Recipients who received partial grafts or multiorgan transplants were excluded. The median follow-up was 4.5 years. The UCLA Institutional Review Board approved the study. The requirement for written informed consent was formally waived because this was a retrospective study. Outcomes after OLT were compared for DCD (n = 7) and DBD (n = 21) donors. Definition of Ischemia Times and Operative Variables A timeline of the phases of ischemic injuries for organs procured after circulatory death and brain death is shown in the Figure. Compared with grafts procured after DBD, the DCD organs are subjected to an additional warm ischemic insult on cessation of life support. The donor warm ischemia time is defined as the interval from withdrawal of life support to initiation of cold organ preservation, graft cold ischemia time as the interval from initiation of in vivo cold organ preservation to removal of the graft from 4 C cold storage, and graft warm ischemia time as the interval from removal from cold storage to reperfusion of the liver graft. Deceased Donor Selection and Protocol The deceased donor selection and organ procurement procedures used the UCLA protocols and techniques for DCD and DBD The DCD donor selection process followed stringent screening criteria: for donor, age younger than 45 years, body mass index (calculated as weight in kilograms divided by height in meters squared) less than 30, hospitalization for 5 or fewer days, and preprocurement serum liver transaminase levels less than twice the normal values at the time of organ acceptance and procurement; for graft, projected duration of organ cold ischemia time less than 8 hours, excellent liver parenchymal quality on intraoperative assessment, and donor warm ischemia time less than 30 minutes. 12 The DCD procurement protocol followed Institute of Medicine guidelines. 15 Artificial life support was withdrawn in the operating room or intensive care unit. Systemic heparin was administered prior to withdrawal of life support if the policies of the organ procurement organizations or donor hospital permitted its use. An independent physician from the donor hospital was assigned to provide end-of-life care, withdraw life support, and declare death. Following a 5-minute mandatory waiting period after asystole to ensure that autoresuscitation did not occur, a rapid procurement technique was performed and cold organ preservation with University of Wisconsin solution (4-6 L) was initiated via the infrarenal aorta. 16 A vascular clamp was applied on the thoracic aorta to confine the circulation of the cold organ preservation solution within the abdominal organs. An incision at the right atrium allowed drainage of blood and effluent fluid. Cold organ preservation solution was also delivered to the portal venous system via the inferior mesenteric vein. Once the 78 JAMA Surgery January 2014 Volume 149, Number 1 jamasurgery.com

3 Liver Transplantation in Children Original Investigation Research Table 1. Recipient Characteristics Characteristic Circulatory Death (n=7) Brain Death (n = 21) P Value Age, median (IQR), mo 28.4 (9.6 to 59.2) 20.1 (11.0 to 31.1).80 Weight, median (IQR), kg 12.0 (7.6 to 18.3) 11.6 (6.9 to 12.8).87 Male, No. (%) 3 (42.9) 9 (42.9) >.99 Liver disease diagnosis, No. (%) Biliary atresia 3 (42.9) 9 (42.9) Acute liver failure 1 (14.3) 3 (14.3) Neonatal hepatitis 1 (14.3) 3 (14.3) Malignant neoplasm 1 (14.3) 3 (14.3) Other 1 (14.3) 3 (14.3) MELD/PELD score, median (IQR) 19 ( 1 to 30) 11 ( 4 to 21) Abbreviations: IQR, interquartile range; MELD/PELD, Model for End-Stage Liver Disease/Pediatric End-Stage Liver Disease. cold organ preservation solution was delivered to the abdominal organs and external organ cooling was achieved, the common bile duct was immediately accessed and University of Wisconsin solution was flushed into the biliary system. Organs were stored in University of Wisconsin solution at 4 C for transport. Beginning in 2006, we initiated a center protocol of administering tissue plasminogen activator to all DCD livers before implantation. Tissue plasminogen activator, in a total dose of 2 mg in 100 ml of sterile water, was injected into the donor hepatic artery on the back table and maintained within the arterial system by a vascular clamp on the artery until vascular anastomosis occurred. Patient Selection and Operative Procedure Patients diagnosed as having end-stage liver disease were evaluated by a multidisciplinary team as previously described. 13 Before 2002, patients were listed for liver transplant candidacy according to the United Network for Organ Sharing status categories; from 2002 to present, the current Model for End-Stage Liver Disease/Pediatric End-Stage Liver Disease (MELD/PELD) system has been used. 11 For patients aged 12 years and older, the MELD scores were calculated on the basis of serum creatinine level, total bilirubin level, and international normalized ratio at the time of OLT. For younger patients (aged <12 years), variables used for PELD scores were serum albumin level, total bilirubin level, international normalized ratio, growth failure (based on sex, weight, and height), and age at listing. The MELD/PELD scoring system ranks children according to their probability of death within 3 months of listing without a liver transplant. A MELD/PELD score of 40 or higher predicts a waiting list mortality of 100%. In this study, the laboratory MELD/PELD scores were used for the analysis. The surgical procedure for OLT was performed in a standard manner as previously described. 17 Recipient, Donor, and Operative Variables Variables collected for analysis included the following: for both recipients and donors, age, race/ethnicity, sex, height, and body weight; for recipients, primary liver disease, MELD/PELD score, and liver test results 1 week and 3, 6, and 12 months following OLT (including serum alanine aminotransferase level, aspartate aminotransferase level, alkaline phosphatase level, total bilirubin level, and international normalized ratio); and for donors, duration of hospitalization before donation, cause of death, need for vasopressors prior to donation, and donor warm ischemia time. Operative variables included graft cold and warm ischemia times. Outcome Measures The primary end point was 10-year graft failure free survival. Graft failure was defined as either the need for retransplantation or death due to primary graft nonfunction or biliary complication. Secondary outcome measures focused on biliary complications, either ischemic cholangiopathy or anastomotic stricture, and vascular complications. Statistical Analysis Graft failure free patient survival curves were computed using Kaplan-Meier methods and compared using log-rank tests. Medians and interquartile ranges of continuous variables were compared using Wilcoxon rank sum test, and proportions of categorical variables were compared using χ 2 test. Statistical analysis was performed using SAS version 9.1 statistical software (SAS Institute, Inc). Results Recipient Characteristics and Severity of Illness Age, weight, and indications for OLT were similar for both groups (Table 1). The most common cause of end-stage liver disease was biliary atresia, followed by acute liver failure, neonatal hepatitis, malignant neoplasm, and other diseases. Regarding acuity of illness at the time of OLT, the median MELD/ PELD score was 19 for the DCD group and 11 for the DBD group (P =.48). The proportion of recipients who required urgent OLT for acute liver failure did not differ between groups. Donor Characteristics and Ischemia Duration Age, weight, sex, cold ischemia time, and warm ischemia time were similar for both groups (Table 2). The median donor age was 24.0 months for DCD and 13.1 months for DBD (P =.72). For the DCD donors, the median donor warm ischemia duration was 24 minutes. jamasurgery.com JAMA Surgery January 2014 Volume 149, Number 1 79

4 Research Original Investigation Liver Transplantation in Children Liver Function, Survival Analysis, and Morbidity Liver test results (Table 3) were compared for the 2 groups at various intervals after OLT. Median peak levels of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and total bilirubin were similar at 1 week and 3, 6, and 12 months. The 10-year graft failure free survivals after OLT were 100% in both DCD and DBD groups. No primary graft nonfunction was observed in either group. Biliary and vascular complications were infrequent in both groups. Anastomotic biliary stricture occurred in 4 patients, 1 after DCD and 3 after DBD. Ischemic cholangiopathy did not occur in either group. There were no arterial complications; portal vein thrombosis occurred in 1 patient in the DBD group and none in the DCD group. There were no retransplantations. Discussion While liver grafts procured after circulatory death have been used to expand the donor pool in adults, there has been reluctance to use this potential organ resource in children. In 2011, only 3 of 474 children (0.6%) in the United States received OLT from DCD donors. 1 Limited use of DCD organs may be owing to the inferior outcomes and higher rates of graft failure and ischemic cholangiopathy reported with grafts from DCD in adult transplantation. 6-10,18 Notwithstanding these complications, DCD liver grafts are precious life-saving organs that can reduce waiting list deaths and have been reported to provide survival benefits in selected patients. 14,19-22 Our study was undertaken to compare long-term outcomes for OLT using DCD and DBD donors in children. Our study shows excellent long-term graft failure free outcomes with liver transplantation in children using DCD organs. Similar to our experience, another single center reported excellent patient and graft survival in children at a median follow-up of 42 months. 23 These findings suggest that outcomes after OLT using DCD grafts in children differ from those in adults. Analysis of the United Network of Organ Sharing database in adult OLT with DCD grafts reported an 85% higher risk for graft failure and a need for retransplantation in 21.6% of patients, compared with 8.8% of patients with DBD grafts. 8,10 In contrast, using the same national registry data, Abtetal 24 reported rates of primary graft nonfunction as 5.3% Table 2. Donor Characteristics and Graft Ischemia Duration Characteristic Circulatory Death (n=7) Brain Death (n = 21) P Value Age, median (IQR), mo 24.0 ( ) 13.1 ( ).72 Weight, median (IQR), kg 12.0 ( ) 11.0 ( ).88 Male, No. (%) 4 (57.1) 12 (57.1) >.99 Donor and graft ischemia duration, median (IQR), min Donor warm ischemia 24 (18-29) NA NA Graft cold ischemia 300 ( ) 420 ( ).41 Graft warm ischemia 39 (32-42) 44 (37-48).13 Abbreviations: IQR, interquartile range; NA, not applicable. Table 3. Comparison of Liver Function Test Results Between Circulatory Death and Brain Death Grafts at Different Intervals After Liver Transplantation Post-OLT Interval 1wk 3mo 6mo 12mo LFT Median (IQR) P Value Median (IQR) P Value Median (IQR) P Value Median (IQR) P Value ALT, U/L DCD 421 ( ) 17 (12-79) 18 (9-50) 13 (7-47) DBD 491 ( ) (16-33) (16-39) (14-57).20 AST, U/L DCD 635 ( ) 26 (20-44) 28 (22-46) 27 (22-36) DBD 902 ( ) (27-47) (26-40) (27-48).28 TB, mg/dl DCD 9.8 ( ) 0.4 ( ) 0.4 ( ) 0.5 ( ) DBD 4.9 ( ) ( ) ( ) ( ).46 AP, U/L DCD 198 ( ) 214 ( ) 222 ( ) 194 ( ) DBD 147 (77-217) ( ) ( ) ( ).64 Abbreviations: ALT, alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate aminotransferase; DBD, donation after brain death; DCD, donation after circulatory death; IQR, interquartile range; LFT, liver function test; OLT, orthotopic liver transplantation; TB, total bilirubin. SI conversion factors: To convert ALT, AP, and AST to microkatals per liter, multiply by ; to convert TB to micromoles per liter, multiply by JAMA Surgery January 2014 Volume 149, Number 1 jamasurgery.com

5 Liver Transplantation in Children Original Investigation Research and a need for retransplantation of the liver as 10.5% of the pediatric patients with DCD grafts. We observed no cases of primary graft nonfunction in our series. Although the data on OLT in children using DCD grafts remain limited, the initial results are superior compared with adult DCD grafts. The difference in outcomes between adults and children might be attributed to both recipient and donor factors. Known risk factors predictive of diminished survival in adult recipients, including recipient characteristics such as hepatitis C or malignant neoplasm and DCD donor characteristics such as graft steatosis, advanced age, and comorbid diseases, are not seen in children. 12 In addition, recipient and donor selection practice in the use of DCD grafts may differ for adults and children based on the patient s risk of death on the waiting list. While the overall waiting list mortality rate for children has declined from 9.5% to 6.2% in the current era, children younger than 6 years have a 4 times higher risk of death while on the waiting list compared with older children aged 11 to 17 years owing to the scarcity of available size-appropriate grafts. 1 Our study supports the use of pediatric DCD grafts in younger and older children, including those with high acuity of illness. Given the excellent long-term outcomes of pediatric DCD grafts compared with other graft variants for small children (partial [segment 2 and 3] grafts from deceased and live donors), a broader use of pediatric DCD grafts has the potential to increase the national organ pool by 4% to 5% and to decrease waiting list deaths of small children in need of transplantation. The superior outcomes from single-center studies suggest that experience in pediatric liver transplantation and the DCD procedure are crucial for optimal results when using DCD grafts. 12,13,23 Although pediatric OLT using DCD grafts represented a small fraction of UCLA s liver transplantation volume, 70% of the pediatric OLTs with DCD grafts in this series were performed a decade after the initiation of our adult DCD program. The application of technical refinements and logistical planning to minimize graft ischemia duration developed from our experience in adult transplantation allowed the successful use of DCD grafts in children. 12,13 We adhered to our criteria on DCD donor selection, donor warm ischemia duration (<30 minutes), and graft cold ischemia duration (<8 hours) and ensured that an experienced surgeon evaluated the graft quality during organ procurement. 12 We also administered organ preservation solution into the biliary tree in vivo during organ procurement and tissue plasminogen activator into the donor hepatic artery at the back table based on data showing potential benefits in reducing ischemic cholangiopathy in adult OLT using DCD grafts. 21 Ischemic cholangiopathy remains a major complication after OLT using DCD grafts in adults. Biliary complications occurred at a higher frequency with DCD compared with DBD grafts (51% vs 33%, respectively), and ischemic cholangiopathy accounted for 13.9% of late graft failure that required retransplantation compared with 0.2% in adult recipients of DBD grafts. 25 Cold ischemic organ preservation has been shown to augment the adverse effects of donor warm ischemia in the development of ischemic cholangiopathy. 7,22 Ischemic cholangiopathy did not develop in children in this study or in a previous study. 23 A possible explanation is that the biliary epithelium in children is more resilient to ischemia and reperfusion injury. Our study and others suggest that the pathophysiological process and outcomes after liver transplantation in children with DCD grafts differ from those in adults. Future studies evaluating the possible mechanisms protecting against ischemic cholangiopathy in pediatric DCD donors would be of value in applying potential treatment targets to minimize the biliary complication and in determining whether the donor warm ischemia duration could be extended beyond the currently acceptable period in adult DCD grafts. This information will facilitate development of a clinical predictive model to guide the use of pediatric DCD grafts for children, similar to the risk stratification system developed in adult transplantation. 12 In summary, our study showed excellent long-term patient survival with liver transplantation using DCD organs in children. Use of liver grafts procured after circulatory death is an effective approach to expand the donor pool and remains an untapped resource for children in need of liver transplantation. ARTICLE INFORMATION Accepted for Publication: April 1, Published Online: November 20, doi: /jamasurg Author Contributions: Dr Hong had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Hong, Venick, Yersiz, Petrowsky, Farmer, McDiarmid, Busuttil. Acquisition of data: Hong, Venick, Yersiz, Kositamongkol, Agopian, Busuttil. Analysis and interpretation of data: Hong, Venick, Kaldas, Hiatt. Drafting of the manuscript: Hong, Venick, Kaldas, Hiatt. Critical revision of the manuscript for important intellectual content: Hong, Venick, Yersiz, Kositamongkol, Petrowsky, Farmer, Agopian, McDiarmid, Hiatt, Busuttil. Statistical analysis: Hong, Venick, Kositamongkol, Petrowsky. Obtained funding: Busuttil. Administrative, technical, or material support: Hong, Venick, Yersiz, Agopian, Busuttil. Study supervision: Hong, Yersiz, Farmer, McDiarmid, Busuttil. Conflict of Interest Disclosures: None reported. Previous Presentation: This study was presented at the 84th Annual Meeting of the Pacific Coast Surgical Association; February 19, 2013; Kauai, Hawaii. REFERENCES 1. Organ Procurement and Transplantation Network; Scientific Registry of Transplant Recipients. OPTN/SRTR 2011 annual data report: liver. /2011. Accessed February 2, Kootstra G. The asystolic, or non-heartbeating, donor.transplantation. 1997;63(7): Monbaliu D, van Pelt J, De Vos R, et al. Primary graft nonfunction and Kupffer cell activation after liver transplantation from non-heart-beating donors in pigs. Liver Transpl. 2007;13(2): Demetris AJ, Lunz JG III, Specht S, Nozaki I. Biliary wound healing, ductular reactions, and IL-6/gp130 signaling in the development of liver disease. World J Gastroenterol. 2006;12(22): Maheshwari A, Maley W, Li Z, Thuluvath PJ. Biliary complications and outcomes of liver transplantation from donors after cardiac death. Liver Transpl. 2007;13(12): Skaro AI, Jay CL, Baker TB, et al. The impact of ischemic cholangiopathy in liver transplantation using donors after cardiac death: the untold story. Surgery. 2009;146(4): jamasurgery.com JAMA Surgery January 2014 Volume 149, Number 1 81

6 Research Original Investigation Liver Transplantation in Children 7. Abt P, Crawford M, Desai N, Markmann J, Olthoff K, Shaked A. Liver transplantation from controlled non-heart-beating donors: an increased incidence of biliary complications. Transplantation. 2003;75(10): Selck FW, Grossman EB, Ratner LE, Renz JF. Utilization, outcomes, and retransplantation of liver allografts from donation after cardiac death: implications for further expansion of the deceased-donor pool. Ann Surg. 2008;248(4): Mateo R, Cho Y, Singh G, et al. Risk factors for graft survival after liver transplantation from donation after cardiac death donors: an analysis of OPTN/UNOS data. Am J Transplant. 2006;6(4): Merion RM, Pelletier SJ, Goodrich N, Englesbe MJ, Delmonico FL. Donation after cardiac death as a strategy to increase deceased donor liver availability. Ann Surg.2006;244(4): Wiesner RH, McDiarmid SV, Kamath PS, et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl. 2001;7(7): Hong JC, Yersiz H, Kositamongkol P, et al. Liver transplantation using organ donation after cardiac death: a clinical predictive index for graft failure-free survival. Arch Surg. 2011;146(9): Busuttil RW, Farmer DG, Yersiz H, et al. Analysis of long-term outcomes of 3200 liver transplantations over two decades: a single-center experience. Ann Surg.2005;241(6): Cameron AM, Ghobrial RM, Yersiz H, et al. Optimal utilization of donor grafts with extended criteria: a single-center experience in over 1000 liver transplants. Ann Surg.2006;243(6): Committee on Non-Heart-Beating Transplantation II: The Scientific and Ethical Basis for Practice and Protocols, Institute of Medicine. Non-Heart-Beating Organ Transplantation: Practice and Protocols. Washington, DC: National Academies Press; Renz J, Yersiz H. The donor operation. In: Busuttil RW, Klintmalm G, eds. Transplantation of the Liver. 2nd ed. Philadelphia, PA: Saunders; 2005: Busuttil RW, Colonna JO II, Hiatt JR, et al. The first 100 liver transplants at UCLA. Ann Surg. 1987;206(4): Orman ES, Barritt AS IV, Wheeler SB, Hayashi PH. Declining liver utilization for transplantation in the United States and the impact of donation after cardiac death.liver Transpl. 2013;19(1): de Vera ME, Lopez-Solis R, Dvorchik I, et al. Liver transplantation using donation after cardiac death donors: long-term follow-up from a single center.am J Transplant. 2009;9(4): Grewal HP, Willingham DL, Nguyen J, et al. Liver transplantation using controlled donation after cardiac death donors: an analysis of a large single-center experience. Liver Transpl. 2009;15(9): Hashimoto K, Eghtesad B, Gunasekaran G, et al. Use of tissue plasminogen activator in liver transplantation from donation after cardiac death donors. Am J Transplant. 2010;10(12): Sanchez-Urdazpal L, Gores GJ, Ward EM, et al. Ischemic-type biliary complications after orthotopic liver transplantation. Hepatology. 1992;16(1): Bartlett A, Vara R, Muiesan P, et al. A single center experience of donation after cardiac death liver transplantation in pediatric recipients. Pediatr Transplant. 2010;14(3): Abt P, Kashyap R, Orloff M, et al. Pediatric liver and kidney transplantation with allografts from DCD donors: a review of UNOS data. Transplantation. 2006;82(12): Bellingham JM, Santhanakrishnan C, Neidlinger N, et al. Donation after cardiac death: a 29-year experience. Surgery. 2011;150(4): JAMA Surgery January 2014 Volume 149, Number 1 jamasurgery.com

Donation after Cardiac Death Liver Transplantation: Predictors of Outcome

Donation after Cardiac Death Liver Transplantation: Predictors of Outcome American Journal of Transplantation 2010; 10: 2512 2519 Wiley Periodicals Inc. C 2010 The Authors Journal compilation C 2010 The American Society of Transplantation and the American Society of Transplant

More information

*6816* 6816 CONSENT FOR DECEASED KIDNEY DONOR ORGAN OPTIONS

*6816* 6816 CONSENT FOR DECEASED KIDNEY DONOR ORGAN OPTIONS The shortage of kidney donors and the ever-increasing waiting list has prompted the transplant community to look at different types of organ donors to meet the needs of our patients on the waiting list.

More information

OMG my LFT s! How to Interpret and Use Them. OMG my LFT s! OMG my LFT s!

OMG my LFT s! How to Interpret and Use Them. OMG my LFT s! OMG my LFT s! How to Interpret and Use Them René Romero, M.D. Clinical Director, Pediatric Hepatology CPG Gastroenterology, Hepatology and Nutrition Emory University School of Medicine Objectives Understand the anatomy

More information

The State of the Liver in the Adult Patient after Fontan Palliation

The State of the Liver in the Adult Patient after Fontan Palliation The State of the Liver in the Adult Patient after Fontan Palliation Fred Wu, M.D. Boston Adult Congenital Heart Service Boston Children s Hospital/Brigham & Women s Hospital 7 th National Adult Congenital

More information

Management of hepatitis C: pre- and post-liver transplantation. Piyawat Komolmit Bangkok

Management of hepatitis C: pre- and post-liver transplantation. Piyawat Komolmit Bangkok Management of hepatitis C: pre- and post-liver transplantation Piyawat Komolmit Bangkok Liver transplantation and CHC Cirrhosis secondary to HCV is the leading cause of liver transplantation in the US

More information

UCLA Asian Liver Program

UCLA Asian Liver Program CLA Program Update Program Faculty Myron J. Tong, PhD, MD Professor of Medicine Hepatology Director, Asian Liver Program Surgery Ronald W. Busuttil, MD, PhD Executive Chair Department of Surgery Director,

More information

Effect of Pretransplant Serum Creatinine on the Survival Benefit of Liver Transplantation

Effect of Pretransplant Serum Creatinine on the Survival Benefit of Liver Transplantation LIVER TRANSPLANTATION 15:1808-1813, 2009 ORIGINAL ARTICLE Effect of Pretransplant Serum Creatinine on the Survival Benefit of Liver Transplantation Pratima Sharma, 1 Douglas E. Schaubel, 2,4 Mary K. Guidinger,

More information

New Kidney Allocation and What it Means to Your Transplant Center and Your Patients

New Kidney Allocation and What it Means to Your Transplant Center and Your Patients New Kidney Allocation and What it Means to Your Transplant Center and Your Patients Alexander Wiseman, M.D. Professor, Division of Renal Diseases and Hypertension Medical Director, Kidney and Pancreas

More information

Where Will my New Kidney Come From?

Where Will my New Kidney Come From? Where Will my New Kidney Come From? The Organ Shortage There is a severe shortage of organs for transplant. This means that the wait for a kidney transplant can be many years. The UW Transplant Program

More information

KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA

KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA O.E. Stakhvoskyi, E.O. Stakhovsky, Y.V. Vitruk, O.A. Voylenko, P.S. Vukalovich, V.A. Kotov, O.M. Gavriluk National Canсer Institute,

More information

Saint Francis Kidney Transplant Program Issue Date: 6/9/15

Saint Francis Kidney Transplant Program Issue Date: 6/9/15 Kidney Transplant Candidate Informed Consent Education Here are educational materials about Kidney Transplant. Please review and read these before your evaluation visit. The RN Transplant Coordinator will

More information

OPTN/UNOS Liver and Intestinal Organ Transplantation Committee Report to the Board of Directors June 25-26, 2012 Richmond, VA.

OPTN/UNOS Liver and Intestinal Organ Transplantation Committee Report to the Board of Directors June 25-26, 2012 Richmond, VA. OPTN/UNOS Liver and Intestinal Organ Transplantation Committee Report to the Board of Directors June 25-26, 2012 Richmond, VA Summary I. Action Items for Board Consideration The Board is asked to approve

More information

Hepatocellular Carcinoma: What the hepatologist wants to know

Hepatocellular Carcinoma: What the hepatologist wants to know Hepatocellular Carcinoma: What the hepatologist wants to know Hélène Castel, MD Liver Unit Hôpital St-Luc CHUM? CAR Annual Scientific Meeting Saturday, April 27 th 2013 Disclosure statement I do not have

More information

LIVER TRANSPLANTATION IN ALAGILLE SYNDROME

LIVER TRANSPLANTATION IN ALAGILLE SYNDROME LIVER TRANSPLANTATION IN ALAGILLE SYNDROME Ronald J. Sokol, MD Children s Hospital Colorado University of Colorado School of Medicine Treatment of Liver Disease in Improve bile flow ALGS Ursodeoxycholic

More information

Approach to Abnormal Liver Tests

Approach to Abnormal Liver Tests Approach to Abnormal Liver Tests Naga P. Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of Gastroenterology and Hepatology Indiana University School

More information

SBRT (Elekta), 45 Gy in fractions of 3 Gy 3x/week for 5 weeks (N=22) vs.

SBRT (Elekta), 45 Gy in fractions of 3 Gy 3x/week for 5 weeks (N=22) vs. Uitgangsvraag 6: Wat is de plaats van stereotactische radiotherapiebehandeling (SBRT) bij HCC patiënten? Primaire studies I Study ID II Method III Patient characteristics IV Intervention(s) V Results primary

More information

How To Decide If You Should Donate To A Transplant

How To Decide If You Should Donate To A Transplant CMA POLICY ORGAN AND TISSUE DONATION AND TRANSPLANTATION (UPDATE 2014) 1. Introduction Advances in surgical techniques, immunosuppressive drugs and supportive medical care have made possible a dramatic

More information

Current status and perspectives in split liver transplantation

Current status and perspectives in split liver transplantation Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.3748/wjg.v21.i39.11003 World J Gastroenterol 2015 October 21; 21(39): 11003-11015 ISSN 1007-9327

More information

Deceased-Donor Renal Transplant Information for patients

Deceased-Donor Renal Transplant Information for patients Deceased-Donor Renal Transplant Information for patients Exceptional healthcare, personally delivered As part of the work-up for the NHS Blood and Transplant (NHSBT) kidney transplant waiting list, you

More information

Liver Function Tests. Dr Stephen Butler Paediatric Advance Trainee TDHB

Liver Function Tests. Dr Stephen Butler Paediatric Advance Trainee TDHB Liver Function Tests Dr Stephen Butler Paediatric Advance Trainee TDHB Introduction Case presentation What is the liver? Overview of tests used to measure liver function RJ 10 month old European girl

More information

Evaluation and Prognosis of Patients with Cirrhosis

Evaluation and Prognosis of Patients with Cirrhosis Evaluation and Prognosis of Patients with Cirrhosis Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded

More information

Term Critical Illness Insurance

Term Critical Illness Insurance Term Critical Illness Insurance PRODUCT GUIDE 5368-01A-JUL14 ASSUMPTION LIFE This document is a summary of the various features of Assumption Life's products. It is neither a contract nor an insurance

More information

How To Pay For Critical Illness Insurance From The Ihc Group

How To Pay For Critical Illness Insurance From The Ihc Group You ve protected your family s financial future by purchasing life and health insurance. Critical Illness Insurance It s cash when you need it. You choose how to spend it. So you can focus on getting well.

More information

Your Guide to Express Critical Illness Insurance Definitions

Your Guide to Express Critical Illness Insurance Definitions Your Guide to Express Critical Illness Insurance Definitions Your Guide to EXPRESS Critical Illness Insurance Definitions This guide to critical illness definitions will help you understand the illnesses

More information

Results of streamlined regional ambulance transport and subsequent treatment of acute abdominal aortic aneurysm

Results of streamlined regional ambulance transport and subsequent treatment of acute abdominal aortic aneurysm CHAPTER 6 Results of streamlined regional ambulance transport and subsequent treatment of acute abdominal aortic aneurysm JW Haveman, A Karliczek, ELG Verhoeven, IFJ Tielliu, R de Vos, JH Zwaveling, JJAM

More information

After the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH

After the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH After the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH Professor of Medicine Department of Gastroenterology Director, Viral Hepatitis Center University of California San Francisco

More information

renal transplantation: A single-center comparative study

renal transplantation: A single-center comparative study Impact of posterior urethral valves on pediatric renal transplantation: A single-center comparative study BY Mohamed Kamal Gheith, MD Oberarzt die Urologie, Universitätsmedizin Mainz Ass. Prof. of Urology,

More information

Wake Forest School of Medicine Department of General Surgery

Wake Forest School of Medicine Department of General Surgery Wake Forest School of Medicine Department of General Surgery TRANSPLANT SURGERY RESIDENT CURRICULUM (PGY-3) OVERVIEW This curriculum has largely been adapted from the curriculum for transplant surgery

More information

Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care

Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

More information

Critical Illness Supplemental Insurance

Critical Illness Supplemental Insurance You ve protected your family s financial future by purchasing life and health insurance. Critical Illness Supplemental Insurance It s cash when you need it. You choose how to spend it. So you can focus

More information

Elevated heart rate at twelve months after heart transplantation is an independent predictor of long term mortality

Elevated heart rate at twelve months after heart transplantation is an independent predictor of long term mortality Elevated heart rate at twelve months after heart transplantation is an independent predictor of long term mortality C. Tomas, MA Castel, E Roig, I. Vallejos, C. Plata, F. Pérez-Villa Cardiology Department,

More information

Case Study in the Management of Patients with Hepatocellular Carcinoma

Case Study in the Management of Patients with Hepatocellular Carcinoma Management of Patients with Viral Hepatitis, Paris, 2004 Case Study in the Management of Patients with Hepatocellular Carcinoma Eugene R. Schiff This 50-year-old married man with three children has a history

More information

Albumin and All-Cause Mortality Risk in Insurance Applicants

Albumin and All-Cause Mortality Risk in Insurance Applicants Copyright E 2010 Journal of Insurance Medicine J Insur Med 2010;42:11 17 MORTALITY Albumin and All-Cause Mortality Risk in Insurance Applicants Michael Fulks, MD; Robert L. Stout, PhD; Vera F. Dolan, MSPH

More information

Clinical Practice Assessment Robotic surgery

Clinical Practice Assessment Robotic surgery Clinical Practice Assessment Robotic surgery Background: Surgery is by nature invasive. Efforts have been made over time to reduce complications and the trauma inherently associated with surgery through

More information

The Whipple Procedure. Sally Hodges, Ph.D.(c) Given the length and difficulty of the procedure, regardless of the diagnosis, certain

The Whipple Procedure. Sally Hodges, Ph.D.(c) Given the length and difficulty of the procedure, regardless of the diagnosis, certain The Whipple Procedure Sally Hodges, Ph.D.(c) Preoperative procedures Given the length and difficulty of the procedure, regardless of the diagnosis, certain assurances must occur prior to offering a patient

More information

Cilostazol versus Clopidogrel after Coronary Stenting

Cilostazol versus Clopidogrel after Coronary Stenting Cilostazol versus Clopidogrel after Coronary Stenting Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine Seoul, Korea AMC, 2004 Background

More information

Impact of MELD-Based Allocation on End-Stage Renal Disease After Liver Transplantation

Impact of MELD-Based Allocation on End-Stage Renal Disease After Liver Transplantation American Journal of Transplantation 2011; 11: 2372 2378 Wiley Periodicals Inc. C Copyright 2011 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/j.1600-6143.2011.03703.x

More information

Using Cost Effectiveness Analysis to Determine Inventory Size for a National Umbilical Cord Blood Bank

Using Cost Effectiveness Analysis to Determine Inventory Size for a National Umbilical Cord Blood Bank Using Cost Effectiveness Analysis to Determine Inventory Size for a National Umbilical Cord Blood Bank Martin Maiers, Bioinformatics National Marrow Donor Program, USA NMDP Minneapolis, MN, USA NATIONAL

More information

ANNUAL REPORT ON KIDNEY TRANSPLANTATION

ANNUAL REPORT ON KIDNEY TRANSPLANTATION ANNUAL REPORT ON KIDNEY TRANSPLANTATION REPORT FOR 2013/2014 (1 APRIL 2004 31 MARCH 2014) PUBLISHED SEPTEMBER 2014 PRODUCED IN COLLABORATION WITH NHS ENGLAND Contents 1 Executive Summary... 1 2 Introduction...

More information

Critical Illness Insurance

Critical Illness Insurance You ve protected your family s financial future by purchasing life and health insurance. Critical Illness Insurance It s cash when you need it. You choose how to spend it. So you can focus on getting well.

More information

David Axelrod, MD, MBA. Associate Professor of Surgery Section Chief- Solid Organ Transplantation Dartmouth- Hitchcock Medical Center

David Axelrod, MD, MBA. Associate Professor of Surgery Section Chief- Solid Organ Transplantation Dartmouth- Hitchcock Medical Center David Axelrod, MD, MBA Associate Professor of Surgery Section Chief- Solid Organ Transplantation Dartmouth- Hitchcock Medical Center Owner of XynManagement which produces software to track and improve

More information

Appendix G - Identification and Selection of Studies

Appendix G - Identification and Selection of Studies FINAL Emergency framework for rationing of blood for massively bleeding patients during a red phase of a Appendix G - Identification and Selection of Studies Inclusion/Exclusion Criteria We included studies

More information

Liver Transplantation for Hepatocellular Carcinoma. John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco

Liver Transplantation for Hepatocellular Carcinoma. John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco Liver Transplantation for Hepatocellular Carcinoma John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco Hepatocellular Carcinoma HCC is the 5th most common

More information

Surgical Site Infection Prevention

Surgical Site Infection Prevention Surgical Site Infection Prevention 1 Objectives 1. Discuss risk factors for SSI 2. Describe evidence-based best practices for SSI prevention 3. State principles of antibiotic prophylaxis 4. Discuss novel

More information

Omega-3 fatty acids improve the diagnosis-related clinical outcome. Critical Care Medicine April 2006;34(4):972-9

Omega-3 fatty acids improve the diagnosis-related clinical outcome. Critical Care Medicine April 2006;34(4):972-9 Omega-3 fatty acids improve the diagnosis-related clinical outcome 1 Critical Care Medicine April 2006;34(4):972-9 Volume 34(4), April 2006, pp 972-979 Heller, Axel R. MD, PhD; Rössler, Susann; Litz, Rainer

More information

NATCO Introductory Education Course Objectives

NATCO Introductory Education Course Objectives NATCO Introductory Education Course for the NEW Transplant Professional & Procurement Professional June 12-15, 2015 Tempe Mission Palms Hotel Tempe, AZ Friday, June 12, 2015 SESSION Course Participants

More information

AN ETHICAL FRAMEWORK FOR CONTROLLED DONATION AFTER CIRCULATORY DEATH

AN ETHICAL FRAMEWORK FOR CONTROLLED DONATION AFTER CIRCULATORY DEATH AN ETHICAL FRAMEWORK FOR CONTROLLED DONATION AFTER CIRCULATORY DEATH UK DONATION ETHICS COMMITTEE DECEMBER 2011 Copyright Academy of Medical Royal Colleges 2011 2 AN ETHICAL FRAMEWORK FOR CONTROLLED DONATION

More information

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:

STROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND: STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention

More information

Using Liver Enzymes as Screening Tests to Predict Mortality Risk

Using Liver Enzymes as Screening Tests to Predict Mortality Risk Copyright E 2008 Journal of Insurance Medicine J Insur Med 2008;40:191 203 LABORATORY TESTING Using Liver Enzymes as Screening Tests to Predict Mortality Risk Michael Fulks, MD; Robert L. Stout, PhD; Vera

More information

W A S H I N G T O N N A T I O N A L WORKSITE. critical illness W2-BR-ER

W A S H I N G T O N N A T I O N A L WORKSITE. critical illness W2-BR-ER W A S H I N G T O N N A T I O N A L WORKSITE critical illness W2-BR-ER More people today are surviving critical illnesses like cancer, heart disease and stroke. But many of the costs to diagnose and treat

More information

PANCREAS, PANCREAS-KIDNEY, SEGMENT OF PANCREAS AND ISLET PANCREATIC TISSUE TRANSPLANTATION SUR703.013

PANCREAS, PANCREAS-KIDNEY, SEGMENT OF PANCREAS AND ISLET PANCREATIC TISSUE TRANSPLANTATION SUR703.013 PANCREAS, PANCREAS-KIDNEY, SEGMENT OF PANCREAS AND ISLET PANCREATIC TISSUE TRANSPLANTATION SUR703.013 COVERAGE: A simultaneous or combined pancreas-kidney transplant (SPK) from a cadaver donor or a simultaneous

More information

Lifecheque Basic Critical Illness Insurance

Lifecheque Basic Critical Illness Insurance Lifecheque Basic Critical Illness Insurance Strong. Reliable. Trustworthy. Forward-thinking. Extra help on the road to recovery Surviving a critical illness can be very challenging financially Few of us

More information

TA L K I N G A B O U T T R A N S P L A N TAT I O N

TA L K I N G A B O U T T R A N S P L A N TAT I O N TA L K I N G A B O U T T R A N S P L A N TAT I O N UNITED NETWORK FOR ORGAN SHARING United Network for Organ Sharing (UNOS) is a private non-profit 501(c)(3) organization that operates the Organ Procurement

More information

Description of the OECD Health Care Quality Indicators as well as indicator-specific information

Description of the OECD Health Care Quality Indicators as well as indicator-specific information Appendix 1. Description of the OECD Health Care Quality Indicators as well as indicator-specific information The numbers after the indicator name refer to the report(s) by OECD and/or THL where the data

More information

Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma (HCC) Abhishek Vadalia Introduction Chemoembolization is being used with increasing frequency in the treatment of solid hepatic tumors such as Hepatocellular Carinoma (HCC) & rare Cholangiocellular Carcinoma

More information

Deceased Organ Donor Potential in Canada

Deceased Organ Donor Potential in Canada Report December 2014 Factors Influencing Health Our Vision Better data. Better decisions. Healthier Canadians. Our Mandate To lead the development and maintenance of comprehensive and integrated health

More information

Preoperative drainage is always indicated in malignant CBD strictures PRO. Horst Neuhaus Evangelisches Krankenhaus Düsseldorf, Germany

Preoperative drainage is always indicated in malignant CBD strictures PRO. Horst Neuhaus Evangelisches Krankenhaus Düsseldorf, Germany Preoperative drainage is always indicated in malignant CBD strictures PRO Horst Neuhaus Evangelisches Krankenhaus Düsseldorf, Germany Background Jaundice is associated with high perioperative morbidity

More information

NP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum

NP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum OVERVIEW OF THE FELLOWSHIP The goal of the AASLD NP/PA Fellowship is to provide a 1-year postgraduate hepatology training program for nurse practitioners and physician assistants in a clinical outpatient

More information

LIMITED BENEFIT HEALTH COVERAGE FOR SPECIFIED CRITICAL ILLNESS. OUTLINE OF COVERAGE (Applicable to Policy Form CI-1.0-NC)

LIMITED BENEFIT HEALTH COVERAGE FOR SPECIFIED CRITICAL ILLNESS. OUTLINE OF COVERAGE (Applicable to Policy Form CI-1.0-NC) COLONIAL LIFE & ACCIDENT INSURANCE COMPANY 1200 Colonial Life Boulevard, P.O. Box 1365, Columbia, South Carolina 29202 1.800.325.4368 www.coloniallife.com A Stock Company LIMITED BENEFIT HEALTH COVERAGE

More information

Opioid Prescribing After Surgical Extraction of Teeth in Medicaid Patients, 2000-2010 FREE ONLINE FIRST

Opioid Prescribing After Surgical Extraction of Teeth in Medicaid Patients, 2000-2010 FREE ONLINE FIRST Opioid Prescribing After Surgical Extraction of Teeth in Medicaid Patients, 2000-2010 FREE ONLINE FIRST James A. Baker, BS 1 ; Jerry Avorn, MD 1 ; Raisa Levin, MS 1 ; Brian T. Bateman, MD, MS 1 [+] Author

More information

Accelerated Death Benefit Endorsements

Accelerated Death Benefit Endorsements Accelerated Death Benefit Endorsements Financial Protection To Help with Critical, Chronic and Terminal Illness Marketing Guide North American Company automatically includes the accelerated death benefit

More information

Organ Donation: A Call for Greater Palliative Care Involvement

Organ Donation: A Call for Greater Palliative Care Involvement Organ Donation: A Call for Greater Palliative Care Involvement Heather A. Harris, M.D. Associate Medical Director, Supportive & Palliative Care Service San Francisco General Hospital & Trauma Center Associate

More information

Organ and Tissue Donation: An Overview

Organ and Tissue Donation: An Overview Organ and Tissue Donation: An Overview E-learning module revised by LifeSource, 2012 This learning module is part of a series of e-learning modules designed to meet hospital education requirements for

More information

U.S. Food and Drug Administration

U.S. Food and Drug Administration U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained

More information

Center Activity (07/01/2009-06/30/2010) Center Region United States Tables for More Information

Center Activity (07/01/2009-06/30/2010) Center Region United States Tables for More Information Program Summary Center Activity (07/01/2009-06/30/2010) Center Region United States Tables for More Information Deceased donor transplants (n=number) 0 169 0 07C,08C,09C On waitlist at start (n) 0 0 0

More information

The child with abnormal liver function tests

The child with abnormal liver function tests The child with abnormal liver function tests Dr Jane Hartley Consultant Paediatric Hepatologist Birmingham Children s Hospital, UK 1 st Global Congress CIP, Paris 2011 Contents Over view of liver anatomy,

More information

Advanced Heart Failure & Transplantation Fellowship Program

Advanced Heart Failure & Transplantation Fellowship Program Advanced Heart Failure & Transplantation Fellowship Program Curriculum I. Patient Care When on the inpatient Heart Failure and Transplant Cardiology service, the cardiology fellow will hold primary responsibility

More information

Liau DW : Injuries and Liability Related to Peripheral Catheters: A Closed Claims Analysis. ASA Newsletter 70(6): 11-13 & 16, 2006.

Liau DW : Injuries and Liability Related to Peripheral Catheters: A Closed Claims Analysis. ASA Newsletter 70(6): 11-13 & 16, 2006. Citation Liau DW : Injuries and Liability Related to Peripheral Catheters: A Closed Claims Analysis. ASA Newsletter 70(6): 11-13 & 16, 2006. Full Text An anesthesiologist inserted a 14-gauge peripheral

More information

FACTORS ASSOCIATED WITH ADVERSE EVENTS IN MAJOR ELECTIVE SPINE, KNEE, AND HIP INPATIENT ORTHOPAEDIC SURGERY

FACTORS ASSOCIATED WITH ADVERSE EVENTS IN MAJOR ELECTIVE SPINE, KNEE, AND HIP INPATIENT ORTHOPAEDIC SURGERY FACTORS ASSOCIATED WITH ADVERSE EVENTS IN MAJOR ELECTIVE SPINE, KNEE, AND HIP INPATIENT ORTHOPAEDIC SURGERY Dov B. Millstone, Anthony V. Perruccio, Elizabeth M. Badley, Y. Raja Rampersaud Dalla Lana School

More information

IINTRODUCTION TO THE DUMONT-UCLA INTESTINAL TRANSPLANT PROGRAM IN THE DUMONT-UCLA TRANSPLANT CENTER

IINTRODUCTION TO THE DUMONT-UCLA INTESTINAL TRANSPLANT PROGRAM IN THE DUMONT-UCLA TRANSPLANT CENTER IINTRODUCTION TO THE DUMONT-UCLA INTESTINAL TRANSPLANT PROGRAM IN THE DUMONT-UCLA TRANSPLANT CENTER Property of The Dumont-UCLA Transplant Center May not be reproduced or distributed in any form without

More information

Creating a Hybrid Database by Adding a POA Modifier and Numerical Laboratory Results to Administrative Claims Data

Creating a Hybrid Database by Adding a POA Modifier and Numerical Laboratory Results to Administrative Claims Data Creating a Hybrid Database by Adding a POA Modifier and Numerical Laboratory Results to Administrative Claims Data Michael Pine, M.D., M.B.A. Michael Pine and Associates, Inc. mpine@consultmpa.com Overview

More information

How does a kidney transplant differ from dialysis?

How does a kidney transplant differ from dialysis? TA L K I N G A B O U T T R A N S P L A N TAT I O N Frequently Asked Questions about Kidney Transplant Evaluation and Listing If your kidneys have stopped working properly, or may stop working soon, you

More information

Guide to Biostatistics

Guide to Biostatistics MedPage Tools Guide to Biostatistics Study Designs Here is a compilation of important epidemiologic and common biostatistical terms used in medical research. You can use it as a reference guide when reading

More information

Hepatitis C. Laboratory Tests and Hepatitis C

Hepatitis C. Laboratory Tests and Hepatitis C Hepatitis C Laboratory Tests and Hepatitis C If you have hepatitis C, your doctor will use laboratory tests to check your health. This handout will help you understand what the major tests are and what

More information

Kidney Transplantation and Cancer - A Review

Kidney Transplantation and Cancer - A Review Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: renal_kidney_transplantation 4/1980 4/2016 4/2017 4/2016 Description of Procedure or Service A kidney transplant

More information

CLINICAL QUALITY MEASURES FINALIZED FOR ELIGIBLE HOSPITALS AND CRITICAL ACCESS HOSPITALS BEGINNING WITH FY 2014

CLINICAL QUALITY MEASURES FINALIZED FOR ELIGIBLE HOSPITALS AND CRITICAL ACCESS HOSPITALS BEGINNING WITH FY 2014 CLINICAL QUALITY MEASURES FINALIZED FOR ELIGIBLE HOSPITALS AND CRITICAL ACCESS HOSPITALS BEGINNING WITH FY 2014 e 55 0495 2 Emergency Department (ED)- 1 Emergency Department Throughput Median time from

More information

Permanent Critical Illness Insurance

Permanent Critical Illness Insurance Permanent Critical Illness Insurance... because we can t predict the future (Home Office) Wouldn t a check be better than a get well card. ADV-1-254IBP & 556IBP & CCLB-Rider Critical Illness Coverage This

More information

What is Health Ethics?

What is Health Ethics? What is Health Ethics? By: Tory Fehrenbacher and Meredith Marston 1. 2. 3. Why is stem cell research ethical? Why is organ donation ethical? Health Ethics: A set of moral principles, beliefs and values

More information

Prevalence of alcohol consumption among Rheumatoid Arthritis patients on Methotrexate and impact on liver function tests

Prevalence of alcohol consumption among Rheumatoid Arthritis patients on Methotrexate and impact on liver function tests Prevalence of alcohol consumption among Rheumatoid Arthritis patients on Methotrexate and impact on liver function tests Christine Iannaccone, MPH, Michelle Frits, Jing Cui, PhD, Michael Weinblatt MD,

More information

INTRAPERITONEAL HYPERTHERMIC CHEMOTHERAPY (IPHC) FOR PERITONEAL CARCINOMATOSIS AND MALIGNANT ASCITES. INFORMATION FOR PATIENTS AND FAMILY MEMBERS

INTRAPERITONEAL HYPERTHERMIC CHEMOTHERAPY (IPHC) FOR PERITONEAL CARCINOMATOSIS AND MALIGNANT ASCITES. INFORMATION FOR PATIENTS AND FAMILY MEMBERS INTRAPERITONEAL HYPERTHERMIC CHEMOTHERAPY (IPHC) FOR PERITONEAL CARCINOMATOSIS AND MALIGNANT ASCITES. INFORMATION FOR PATIENTS AND FAMILY MEMBERS Description of Treatment A major difficulty in treating

More information

Transplant Coordinator

Transplant Coordinator Have you signed your organ donor card? Hearts, kidneys, livers, and lungs can all be transplanted. When you die, one of your organs could help a critically ill patient live a longer life. What I do every

More information

Ischemia and Infarction

Ischemia and Infarction Harvard-MIT Division of Health Sciences and Technology HST.035: Principle and Practice of Human Pathology Dr. Badizadegan Ischemia and Infarction HST.035 Spring 2003 In the US: ~50% of deaths are due to

More information

The Timber. Critical Illness Insurance Plans. Safeguard You and Your Family with

The Timber. Critical Illness Insurance Plans. Safeguard You and Your Family with Safeguard You and Your Family with The Timber Ridge Series Critical Illness Insurance Plans The Plan consists of: A renewable and convertible term life policy with a critical condition accelerated benefit

More information

Tranexamic Acid. Tranexamic Acid. Overview. Blood Conservation Strategies. Blood Conservation Strategies. Blood Conservation Strategies

Tranexamic Acid. Tranexamic Acid. Overview. Blood Conservation Strategies. Blood Conservation Strategies. Blood Conservation Strategies Overview Where We Use It And Why Andreas Antoniou, M.D., M.Sc. Department of Anesthesia and Perioperative Medicine University of Western Ontario November 14 th, 2009 Hemostasis Fibrinolysis Aprotinin and

More information

Objectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History

Objectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History Preoperative Cardiac Risk Stratification for Noncardiac Surgery Kimberly Boddicker, MD FACC Essentia Health Heart and Vascular Center 27 th Heart and Vascular Conference May 13, 2011 Objectives Summarize

More information

Journal reading. Method. Introduction. Measurement. Supervisor: F1 徐 英 洲 Presentor:R1 劉 邦 民 103.04.14

Journal reading. Method. Introduction. Measurement. Supervisor: F1 徐 英 洲 Presentor:R1 劉 邦 民 103.04.14 Journal reading Supervisor: F1 徐 英 洲 Presentor:R1 劉 邦 民 103.04.14 Introduction Epinephrine usage in CPR Pro: Ability to augment BP and increased coronary perfusion through systemic vasoconstriction Cons:

More information

The Initial and 24 h (After the Patient Rehabilitation) Deficit of Arterial Blood Gases as Predictors of Patients Outcome

The Initial and 24 h (After the Patient Rehabilitation) Deficit of Arterial Blood Gases as Predictors of Patients Outcome Biomedical & Pharmacology Journal Vol. 6(2), 259-264 (2013) The Initial and 24 h (After the Patient Rehabilitation) Deficit of Arterial Blood Gases as Predictors of Patients Outcome Vadod Norouzi 1, Ali

More information

ATTACHMENT I TO APPENDIX B OF UNOS BYLAWS

ATTACHMENT I TO APPENDIX B OF UNOS BYLAWS ATTACHMENT I TO APPENDIX B OF UNOS BYLAWS Designated Transplant Program Criteria XIII. Transplant Programs. A. In order to qualify for membership, a transplant program must utilize, for its histocompatibility

More information

GT-020 Phase 1 Clinical Trial: Results of Second Cohort

GT-020 Phase 1 Clinical Trial: Results of Second Cohort GT-020 Phase 1 Clinical Trial: Results of Second Cohort July 29, 2014 NASDAQ: GALT www.galectintherapeutics.com 2014 Galectin Therapeutics inc. Forward-Looking Statement This presentation contains, in

More information

Main Effect of Screening for Coronary Artery Disease Using CT

Main Effect of Screening for Coronary Artery Disease Using CT Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,

More information

Prognostic impact of uric acid in patients with stable coronary artery disease

Prognostic impact of uric acid in patients with stable coronary artery disease Prognostic impact of uric acid in patients with stable coronary artery disease Gjin Ndrepepa, Siegmund Braun, Martin Hadamitzky, Massimiliano Fusaro, Hans-Ullrich Haase, Kathrin A. Birkmeier, Albert Schomig,

More information

Kidneys. Kidney Failure4. Transplantation

Kidneys. Kidney Failure4. Transplantation Kidneys & Kidney Failure4 Transplantation This booklet helps you understand the process of transplantation. It defines the criteria for a donor and the recipient. It also clearly explains the concepts

More information

THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT

THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological

More information

Medical Coverage Policy Bariatric Surgery

Medical Coverage Policy Bariatric Surgery Medical Coverage Policy Bariatric Surgery Device/Equipment Drug Medical Surgery Test Other Effective Date: 9/1/2011 Policy Last Updated: 11/01/2011 Prospective review is recommended/required. Please check

More information

Resection of Lung Cancer Invading the Mediastinum

Resection of Lung Cancer Invading the Mediastinum Resection of Lung Cancer Invading the Mediastinum Philippe G. Dartevelle MARIE-LANNELONGUE HOSPITAL GUSTAVE ROUSSY INSTITUTE INSTITUTE OF THORACIC ONCOLOGY PARIS SUD UNIVERSITY Mediastinal Invasion Superior

More information

Elements for a Public Summary

Elements for a Public Summary VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Hunter syndrome is a rare genetic disease which mainly affects males of all ethnicities. The incidence rate ranges from 0.6 to

More information

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer

L Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,

More information

Enzyme Replacement Therapies for UCD (Liver/ Liver Cell / Stem Cell Transplantation) Pat McKiernan Birmingham Children s Hospital

Enzyme Replacement Therapies for UCD (Liver/ Liver Cell / Stem Cell Transplantation) Pat McKiernan Birmingham Children s Hospital Enzyme Replacement Therapies for UCD (Liver/ Liver Cell / Stem Cell Transplantation) Pat McKiernan Birmingham Children s Hospital Survival following liver transplantation for Biliary Atresia at BCH (n=195)

More information

QUESTIONS FOR LEUVEN CASE (B)

QUESTIONS FOR LEUVEN CASE (B) Brandeis University The Heller School for Social Policy & Management QUESTIONS FOR LEUVEN CASE (B) Jon Chilingerian, Ph.D Email: chilinge@brandeis.edu Managing Clinics, Care Processes and the Physics of

More information

Gruppo di lavoro: Malattie Tromboemboliche

Gruppo di lavoro: Malattie Tromboemboliche Gruppo di lavoro: Malattie Tromboemboliche 2381 Soluble Recombinant Thrombomodulin Ameliorates Hematological Malignancy-Induced Disseminated Intravascular Coagulation More Promptly Than Conventional Anticoagulant

More information